专题：Protein Kinase Regulation and GTPase Signaling

This cluster of papers focuses on the molecular mechanisms of Ras signaling pathways, including the role of protein kinases, GTPases, and phospholipase C in cell regulation and cancer therapy. It explores the involvement of calcium signaling, cell migration, and transcriptional regulation in oncogenic mutations.
最新文献
Calprotectin: An Overview

article Full Text OpenAlex

How Functional Variants Reconfigure the Rac2 Conformational Landscape

article Full Text OpenAlex

A phase II basket trial of vosoritide in children with RASopathies, ACAN, and NPR2 deficiency

article Full Text OpenAlex

The impact of K-Ras Gly12 mutants on homeostasis and tumorigenesis in the colonic epithelium

article Full Text OpenAlex

Targeting TROP‑2 in treatment‑resistant non‑small cell lung cancer harboring the KRAS G12C mutation and TROP‑2 upregulation: A case report

article Full Text OpenAlex

Inhibition of adenylyl cyclase 1 or exchange protein activated by cAMP restores ATP‐sensitive potassium channel activity after chronic opioid exposure

article Full Text OpenAlex

The heart of the matter: a personal view of Fred Wittinghofer’s contributions to RAS biology and drug design

article Full Text OpenAlex

Antipsychotic-like effects of the selective Rho-kinase 2 inhibitor KD025 in genetic and pharmacological mouse models of schizophrenia

article Full Text OpenAlex

Undetected mutations across different serum alpha1 antitrypsin thresholds: An analysis of the avatar cohort

article Full Text OpenAlex

In silico evaluation of itaconic acid as a potential inhibitor of KRAS and PPARG proteins in lung cancer

article Full Text OpenAlex

近5年高被引文献
Multifaceted role of mTOR (mammalian target of rapamycin) signaling pathway in human health and disease

review Full Text OpenAlex 793 FWCI117.2849

An atlas of substrate specificities for the human serine/threonine kinome

article Full Text OpenAlex 676 FWCI95.87

Anti-tumor efficacy of a potent and selective non-covalent KRASG12D inhibitor

article Full Text OpenAlex 495 FWCI37.7006

Pan-KRAS inhibitor disables oncogenic signalling and tumour growth

article Full Text OpenAlex 478 FWCI70.7849

Adagrasib with or without Cetuximab in Colorectal Cancer with Mutated KRAS G12C

article Full Text OpenAlex 469 FWCI43.914

Sotorasib plus Panitumumab in Refractory Colorectal Cancer with Mutated KRAS G12C

article Full Text OpenAlex 326 FWCI71.9747

Expanding the Reach of Precision Oncology by Drugging All KRAS Mutants

article Full Text OpenAlex 303 FWCI23.747

Concurrent inhibition of oncogenic and wild-type RAS-GTP for cancer therapy

article Full Text OpenAlex 302 FWCI65.1624

Single-Agent Divarasib (GDC-6036) in Solid Tumors with a KRAS G12C Mutation

article Full Text OpenAlex 281 FWCI41.448

Translational and Therapeutic Evaluation of RAS-GTP Inhibition by RMC-6236 in RAS-Driven Cancers

article Full Text OpenAlex 262 FWCI56.919